HMGB1 and Sepsis: A recombinant human soluble TM (rhsTM) has been recently developed [6], and this new agent has some advantages over APC such as a long in vivo half-life and a unique amino-terminal structure exhibiting anti-inflammatory activity including sequestration [7] and cleavage of high-mobility group box 1 (HMGB1) [8], recently identified as a lethal late-phase mediator and is suspected to be closely correlated with the development of disseminated intravascular coagulation (DIC) during sepsis [9].